#321 Iosif Gershteyn; CEO of ImmuVia, a BioTech Company Focusing on Hard-To-Treat Cancers episode artwork

EPISODE · Sep 27, 2023 · 1H 16M

#321 Iosif Gershteyn; CEO of ImmuVia, a BioTech Company Focusing on Hard-To-Treat Cancers

from The Vance Crowe Podcast · host Vance Crowe

Iosif Gershteyn is the CEO of the company ImmuVia, a biotechnology company focused on oncological diseases, specifically hard-to-treat cancers.  He discusses his work with his company ImmuVia, as well as his childhood experience in Russia & talks on many different angles of philosophy.essay mentionedImmuVia: https://immuviatx.com/For more philosophy: https://visionxform.com/-Book a Legacy Interview | https://legacyinterviews.com/ —A Legacy Interview is a two-hour recorded interview with you and a host that can be watched now and viewed in the future. It is a recording of what you experienced, the lessons you learned and the family values you want passed down. We will interview you or a loved one, capturing the sound of their voice, wisdom and a sense of who they are. These recorded conversations will be private, reserved only for the people that you want to share it with.

Episode metadata supplied by the publisher feed · Published Sep 27, 2023

Embed this episode

Ready to play

#321 Iosif Gershteyn; CEO of ImmuVia, a BioTech Company Focusing on Hard-To-Treat Cancers

0:00 1:16:15

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Vance Crowe Podcast?

This episode is 1 hour and 16 minutes long.

When was this The Vance Crowe Podcast episode published?

This episode was published on September 27, 2023.

Can I download this The Vance Crowe Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!